BRPI0609043A2 - uso de um composto, composto, composição farmacêutica, e, método para a preparação de composições farmacêuticas - Google Patents

uso de um composto, composto, composição farmacêutica, e, método para a preparação de composições farmacêuticas Download PDF

Info

Publication number: BRPI0609043A2
Authority: BR; Brazil
Prior art keywords: disorders; formula; compound; phenyl; hydrogen
Prior art date: 2005-02-24

Application number

BRPI0609043-5A

Other languages

English (en)

Portuguese (pt)

Inventor

Benjamin Drukarch

Anton N M Schoffelmeer

Roelof W Feenstra

Marie-Odile Christen

Jean-Louis Burgot

Marylene Chollet

Vliet Bernard J Van Van

Martinus Th M Tulp

Wouter I Iwema Bakker

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-24

Filing date

2006-02-17

Publication date

2010-11-16

2006-02-17 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2010-11-16 Publication of BRPI0609043A2 publication Critical patent/BRPI0609043A2/pt

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 89
238000000034 method Methods 0.000 title claims abstract description 23
238000002360 preparation method Methods 0.000 title claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
239000003814 drug Substances 0.000 claims abstract description 10
LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical class S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 claims abstract description 6
230000002265 prevention Effects 0.000 claims abstract description 5
-1 bromo, hydroxy Chemical group 0.000 claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 17
208000035475 disorder Diseases 0.000 claims description 17
239000001257 hydrogen Substances 0.000 claims description 16
229910052739 hydrogen Inorganic materials 0.000 claims description 16
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
150000001204 N-oxides Chemical class 0.000 claims description 14
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
125000003118 aryl group Chemical group 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 11
229920002472 Starch Polymers 0.000 claims description 10
239000008107 starch Substances 0.000 claims description 10
235000019698 starch Nutrition 0.000 claims description 10
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
229910052760 oxygen Inorganic materials 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
229910052717 sulfur Inorganic materials 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
239000000460 chlorine Substances 0.000 claims description 7
125000004093 cyano group Chemical group *C#N 0.000 claims description 7
125000001424 substituent group Chemical group 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
125000002252 acyl group Chemical group 0.000 claims description 6
125000003282 alkyl amino group Chemical group 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
125000004663 dialkyl amino group Chemical group 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 6
239000011593 sulfur Substances 0.000 claims description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
208000020401 Depressive disease Diseases 0.000 claims description 5
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
125000004423 acyloxy group Chemical group 0.000 claims description 5
125000004414 alkyl thio group Chemical group 0.000 claims description 5
125000005110 aryl thio group Chemical group 0.000 claims description 5
125000004104 aryloxy group Chemical group 0.000 claims description 5
239000011737 fluorine Substances 0.000 claims description 5
229910052731 fluorine Inorganic materials 0.000 claims description 5
125000005842 heteroatom Chemical group 0.000 claims description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
208000011117 substance-related disease Diseases 0.000 claims description 5
208000020925 Bipolar disease Diseases 0.000 claims description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
208000005392 Spasm Diseases 0.000 claims description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
125000001769 aryl amino group Chemical group 0.000 claims description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
150000004677 hydrates Chemical class 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
125000004043 oxo group Chemical group O=* 0.000 claims description 4
210000002460 smooth muscle Anatomy 0.000 claims description 4
239000012453 solvate Substances 0.000 claims description 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
208000000884 Airway Obstruction Diseases 0.000 claims description 3
208000019901 Anxiety disease Diseases 0.000 claims description 3
206010069632 Bladder dysfunction Diseases 0.000 claims description 3
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
208000030814 Eating disease Diseases 0.000 claims description 3
208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
208000001613 Gambling Diseases 0.000 claims description 3
208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 3
208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
206010019233 Headaches Diseases 0.000 claims description 3
208000030990 Impulse-control disease Diseases 0.000 claims description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
206010034158 Pathological gambling Diseases 0.000 claims description 3
201000001880 Sexual dysfunction Diseases 0.000 claims description 3
206010041250 Social phobia Diseases 0.000 claims description 3
208000027520 Somatoform disease Diseases 0.000 claims description 3
208000000323 Tourette Syndrome Diseases 0.000 claims description 3
125000003302 alkenyloxy group Chemical group 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
208000022371 chronic pain syndrome Diseases 0.000 claims description 3
235000014632 disordered eating Nutrition 0.000 claims description 3
208000024732 dysthymic disease Diseases 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
208000029364 generalized anxiety disease Diseases 0.000 claims description 3
231100000869 headache Toxicity 0.000 claims description 3
208000014617 hemorrhoid Diseases 0.000 claims description 3
208000024714 major depressive disease Diseases 0.000 claims description 3
201000003631 narcolepsy Diseases 0.000 claims description 3
CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 claims description 3
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
208000027753 pain disease Diseases 0.000 claims description 3
208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
125000003373 pyrazinyl group Chemical group 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
208000012672 seasonal affective disease Diseases 0.000 claims description 3
231100000872 sexual dysfunction Toxicity 0.000 claims description 3
210000005070 sphincter Anatomy 0.000 claims description 3
208000016686 tic disease Diseases 0.000 claims description 3
MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 claims description 2
QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 2
KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 claims description 2
208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
206010006550 Bulimia nervosa Diseases 0.000 claims description 2
201000009916 Postpartum depression Diseases 0.000 claims description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
206010038743 Restlessness Diseases 0.000 claims description 2
125000002431 aminoalkoxy group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
208000019906 panic disease Diseases 0.000 claims description 2
208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 2
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
229930192474 thiophene Natural products 0.000 claims description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
208000013403 hyperactivity Diseases 0.000 claims 1
239000008188 pellet Substances 0.000 claims 1
230000001960 triggered effect Effects 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 abstract description 11
238000003786 synthesis reaction Methods 0.000 abstract description 10
239000003112 inhibitor Substances 0.000 abstract description 7
238000004519 manufacturing process Methods 0.000 abstract description 7
239000002899 monoamine oxidase inhibitor Substances 0.000 abstract description 6
230000009286 beneficial effect Effects 0.000 abstract description 3
230000004064 dysfunction Effects 0.000 abstract description 3
239000000543 intermediate Substances 0.000 abstract description 2
230000005062 synaptic transmission Effects 0.000 abstract 1
102000010909 Monoamine Oxidase Human genes 0.000 description 40
108010062431 Monoamine oxidase Proteins 0.000 description 40
230000000694 effects Effects 0.000 description 29
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000000243 solution Substances 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
239000002904 solvent Substances 0.000 description 13
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
201000010099 disease Diseases 0.000 description 11
238000002844 melting Methods 0.000 description 11
230000008018 melting Effects 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
239000003480 eluent Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 9
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
239000013078 crystal Substances 0.000 description 8
239000007787 solid Substances 0.000 description 8
RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 8
DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
239000003921 oil Substances 0.000 description 7
235000019198 oils Nutrition 0.000 description 7
238000003756 stirring Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
239000000651 prodrug Substances 0.000 description 6
229940002612 prodrug Drugs 0.000 description 6
239000000047 product Substances 0.000 description 6
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 5
239000002274 desiccant Substances 0.000 description 5
238000001914 filtration Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
229910004298 SiO 2 Inorganic materials 0.000 description 4
229940011037 anethole Drugs 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
235000019439 ethyl acetate Nutrition 0.000 description 4
239000011521 glass Substances 0.000 description 4
RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
150000003512 tertiary amines Chemical class 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
208000007101 Muscle Cramp Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229940082992 antihypertensives mao inhibitors Drugs 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000000605 extraction Methods 0.000 description 3
125000004356 hydroxy functional group Chemical group O* 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229960003732 tyramine Drugs 0.000 description 3
MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical class CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108010003989 D-amino-acid oxidase Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
208000016620 Tourette disease Diseases 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000011324 bead Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229950002858 clorgiline Drugs 0.000 description 2
BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 2
229910052681 coesite Inorganic materials 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
229910052906 cristobalite Inorganic materials 0.000 description 2
230000006735 deficit Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000000284 extract Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
229910052682 stishovite Inorganic materials 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229910052905 tridymite Inorganic materials 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
VXLBSYHAEKDUSU-JXMROGBWSA-N (2e)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine Chemical compound NC\C(=C\F)CCC1=CC=C(F)C=C1 VXLBSYHAEKDUSU-JXMROGBWSA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
MUZIZEZCKKMZRT-UHFFFAOYSA-N 1,2-dithiolane Chemical class C1CSSC1 MUZIZEZCKKMZRT-UHFFFAOYSA-N 0.000 description 1
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical class C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
VRVRKVMNULDZPO-UHFFFAOYSA-N 1,3-oxazole;1,3-thiazole Chemical compound C1=COC=N1.C1=CSC=N1 VRVRKVMNULDZPO-UHFFFAOYSA-N 0.000 description 1
XJWVCWQKZQENDS-UHFFFAOYSA-N 1-bromopropan-2-ylbenzene Chemical compound BrCC(C)C1=CC=CC=C1 XJWVCWQKZQENDS-UHFFFAOYSA-N 0.000 description 1
OWFFSLCGWLZYDH-UHFFFAOYSA-N 1-hexoxy-4-prop-1-en-2-ylbenzene Chemical compound CCCCCCOC1=CC=C(C(C)=C)C=C1 OWFFSLCGWLZYDH-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
MNFZZNNFORDXSV-UHFFFAOYSA-N 4-(diethylamino)benzaldehyde Chemical compound CCN(CC)C1=CC=C(C=O)C=C1 MNFZZNNFORDXSV-UHFFFAOYSA-N 0.000 description 1
LVSQXDHWDCMMRJ-UHFFFAOYSA-N 4-hydroxybutan-2-one Chemical compound CC(=O)CCO LVSQXDHWDCMMRJ-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
LEPDMIYUICCABX-UHFFFAOYSA-N 5-methyldithiole-3-thione Chemical compound CC1=CC(=S)SS1 LEPDMIYUICCABX-UHFFFAOYSA-N 0.000 description 1
QBCPCKKWZGQFNP-UHFFFAOYSA-N 5-methylsulfanyl-4-phenyldithiole-3-thione Chemical compound S1SC(=S)C(C=2C=CC=CC=2)=C1SC QBCPCKKWZGQFNP-UHFFFAOYSA-N 0.000 description 1
SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
208000008811 Agoraphobia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
102000004674 D-amino-acid oxidase Human genes 0.000 description 1
102100026908 D-amino-acid oxidase Human genes 0.000 description 1
206010012218 Delirium Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012390 Depression postoperative Diseases 0.000 description 1
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000000913 Kidney Calculi Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
208000029578 Muscle disease Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
229910004809 Na2 SO4 Inorganic materials 0.000 description 1
206010029148 Nephrolithiasis Diseases 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
206010030043 Ocular hypertension Diseases 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
206010065508 Orthostatic hypertension Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000006399 Premature Obstetric Labor Diseases 0.000 description 1
206010036600 Premature labour Diseases 0.000 description 1
201000003099 Renovascular Hypertension Diseases 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000011949 advanced processing technology Methods 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
208000022257 bipolar II disease Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000019771 cognition Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002081 enamines Chemical class 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229950005862 lazabemide Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229950010854 mofegiline Drugs 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000001730 monoaminergic effect Effects 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000000956 myotropic effect Effects 0.000 description 1
JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229950008687 oltipraz Drugs 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
208000026440 premature labor Diseases 0.000 description 1
JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
229960000245 rasagiline Drugs 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
230000036280 sedation Effects 0.000 description 1
MEZLKOACVSPNER-UHFFFAOYSA-N selegiline Chemical compound C#CCN(C)C(C)CC1=CC=CC=C1 MEZLKOACVSPNER-UHFFFAOYSA-N 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
229960004628 tyramine hcl Drugs 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

BRPI0609043-5A 2005-02-24 2006-02-17 uso de um composto, composto, composição farmacêutica, e, método para a preparação de composições farmacêuticas BRPI0609043A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05101405		2005-02-24
EP05101405.8		2005-02-24
PCT/EP2006/060060 WO2006089861A2 (en)	2005-02-24	2006-02-17	Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission

Publications (1)

Publication Number	Publication Date
BRPI0609043A2 true BRPI0609043A2 (pt)	2010-11-16

Family

ID=34938805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0609043-5A BRPI0609043A2 (pt)	2005-02-24	2006-02-17	uso de um composto, composto, composição farmacêutica, e, método para a preparação de composições farmacêuticas

Country Status (14)

Country	Link
EP (1)	EP1858875A2 (ar)
JP (1)	JP2008531519A (ar)
KR (1)	KR20070117607A (ar)
CN (1)	CN101107240B (ar)
AR (1)	AR055862A1 (ar)
AU (1)	AU2006218012A1 (ar)
BR (1)	BRPI0609043A2 (ar)
CA (1)	CA2594165A1 (ar)
MX (1)	MX2007010380A (ar)
RU (1)	RU2402543C2 (ar)
SA (1)	SA06270023B1 (ar)
TW (1)	TW200640898A (ar)
UA (1)	UA94579C2 (ar)
WO (1)	WO2006089861A2 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0704718D0 (en) *	2007-03-12	2007-04-18	Prendergast Patrick T	Compounds and methods for preventing and treating mucositis
CN102807557B (zh) *	2012-08-21	2015-02-04	苏州大学	3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用
KR101438415B1 (ko) *	2013-07-25	2014-09-17	동국대학교 경주캠퍼스 산학협력단	기억력 손상의 예방 또는 개선을 위한 조구등 추출물
CN104788440B (zh) *	2015-04-03	2017-12-26	苏州大学	烟酸衍生物及其应用
FR3063640B1 (fr) *	2017-03-07	2020-10-09	Elodie Petitjean	Traitement de la fibrose pulmonaire a l'aide d'un inhibiteur selectif de la production d'especes reactives de l'oxygene d'origine mitochondriale
CA3055122A1 (en)	2017-03-07	2018-09-13	OP2 Drugs	Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
WO2020058767A1 (en) *	2018-09-18	2020-03-26	St Ip Holding Ag	Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1442450A (fr) *	1964-05-05	1966-06-17	Monsanto Chemicals	Nouveaux composés hétérocycliques contenant du soufre
JPH089611B2 (ja) *	1988-06-20	1996-01-31	三井東圧化学株式会社	新規１，２−ジチオール−３−チオン誘導体およびそれを有効成分とする免疫調節剤
AU5474198A (en) *	1996-12-24	1998-07-17	National Research Council Of Canada	Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
AU6462500A (en) *	1999-07-29	2001-02-19	Patrick T. Prendergast	Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

2006
- 2006-02-16 TW TW095105223A patent/TW200640898A/zh unknown
- 2006-02-17 JP JP2007556592A patent/JP2008531519A/ja not_active Withdrawn
- 2006-02-17 MX MX2007010380A patent/MX2007010380A/es unknown
- 2006-02-17 KR KR1020077021935A patent/KR20070117607A/ko not_active Ceased
- 2006-02-17 EP EP06708351A patent/EP1858875A2/en not_active Withdrawn
- 2006-02-17 BR BRPI0609043-5A patent/BRPI0609043A2/pt not_active IP Right Cessation
- 2006-02-17 UA UAA200710593A patent/UA94579C2/ru unknown
- 2006-02-17 AU AU2006218012A patent/AU2006218012A1/en not_active Abandoned
- 2006-02-17 WO PCT/EP2006/060060 patent/WO2006089861A2/en not_active Ceased
- 2006-02-17 CN CN2006800030655A patent/CN101107240B/zh not_active Expired - Fee Related
- 2006-02-17 RU RU2007135184/04A patent/RU2402543C2/ru not_active IP Right Cessation
- 2006-02-17 CA CA002594165A patent/CA2594165A1/en not_active Abandoned
- 2006-02-21 SA SA06270023A patent/SA06270023B1/ar unknown
- 2006-02-21 AR ARP060100616A patent/AR055862A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN101107240A (zh)	2008-01-16
MX2007010380A (es)	2007-09-25
AU2006218012A1 (en)	2006-08-31
RU2007135184A (ru)	2009-03-27
AR055862A1 (es)	2007-09-12
UA94579C2 (ru)	2011-05-25
JP2008531519A (ja)	2008-08-14
WO2006089861A3 (en)	2006-10-26
SA06270023A (ar)	2005-12-03
CN101107240B (zh)	2011-02-09
CA2594165A1 (en)	2006-08-31
KR20070117607A (ko)	2007-12-12
EP1858875A2 (en)	2007-11-28
RU2402543C2 (ru)	2010-10-27
SA06270023B1 (ar)	2010-10-12
TW200640898A (en)	2006-12-01
WO2006089861A2 (en)	2006-08-31

Legal Events

Date	Code	Title	Description
2010-08-10	B06G	Technical and formal requirements: other requirements [chapter 6.7 patent gazette]	Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.
2013-05-28	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUI DADE.
2014-02-11	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013.

Publication	Publication Date	Title
ES2243044T3 (es)	2005-11-16	Derivados de sulfonamida para el tratamiento de trastornos del snc.
US5326770A (en)	1994-07-05	Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
FI91634B (fi)	1994-04-15	Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi
JP4740116B2 (ja)	2011-08-03	精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
HU211463A9 (en)	1995-11-28	Propenone oxim ethers, method for preparing them and pharmaceutical compositions containing them
ES2224429T3 (es)	2005-03-01	Derivados de indano sustituido.
JP2007523128A (ja)	2007-08-16	Ｃｂ１−アンタゴニスト活性を有するイミダゾリン誘導体
BRPI0609043A2 (pt)	2010-11-16	uso de um composto, composto, composição farmacêutica, e, método para a preparação de composições farmacêuticas
JP7523146B2 (ja)	2024-07-26	Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体
CA2274055A1 (en)	1998-06-25	N-piperazin-1-ylphenyl-benzamide derivatives
BRPI0806452A2 (pt)	2011-09-06	compostos, medicamento, composição farmacêutica, e, uso de um composto
JPH01294670A (ja)	1989-11-28	２−（ピペラジニル）−２−オキソエチレン−置換フラボノイド誘導体、その製法およびそれを含有する医薬組成物
SK138993A3 (en)	1994-11-09	Amidoalkyl - and imidoalkylpiperazines
JP4454622B2 (ja)	2010-04-21	アルファ−１アドレナリン作動性アゴニストとしてのメチルインドール及びメチルピロロピリジン
EP0367040B1 (en)	1993-04-21	Compounds for the treatment of urinary incontinence
US5834460A (en)	1998-11-10	Serine derivative
US20060194971A1 (en)	2006-08-31	Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission
CN101735207B (zh)	2011-11-02	含γ亚基丁烯内酯基团的地洛他定衍生物及其合成方法
JP4575167B2 (ja)	2010-11-04	置換ベンゾジオキセピン
CA1093582A (fr)	1981-01-13	Procede d'obtention de nouvelles propylenediamines
MX2007006756A (es)	2007-11-09	Fenilpiperazinas con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina.
PT99250B (pt)	1999-04-30	Processo para a preparacao de derivados de piperazina
CZ281936B6 (cs)	1997-04-16	Ethery oximů thieno-cyklopentanonů, jejich sole, způsoby jejich přípravy a farmaceutické prostředky, které je obsahují
US5096902A (en)	1992-03-17	Heterocyclic compounds containing nitrogen and sulfur, pharmaceutical compositions containing them and process for preparing same
HK1113929A (en)	2008-10-17	Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission